Sanofi stock
SAN.PAPARHealthcareISIN FR0000120578
67Score 67 out of 100, Neutral
Price and trend
62 / 100
Price history
−2.4% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since May 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 95).
The price is at its 52-week high. Largest decline in 20 years: 47% (May 2007 to October 2008).
Chart figures for advanced users
- SMA 50$83.87
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$85.53
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)95
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$77.88
- The lowest closing price of the last twelve months.
- Resistance$97.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sanofi belongs to the Drug Manufacturers (General) industry (France) and, with a market value of $117.29B, is number 13 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $51.98B (up 5.5% year on year) and earnings of $8.69B (up 40.5%).
- For fiscal 2026, analysts expect on average revenue of $55.33B (up 6.5%) and adjusted earnings per share of $9.54 (down 3.8%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 188 of 714 in Healthcare, median 53.
- Our model puts fair value at $192.84, with the price 50% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 215% of earnings over the last 12 months.Fundamentals 87
- Reliable dividendNo dividend cut for over 26 years.Capital allocation 66
- Below fair valuePrice 50% below the fair value of $192.84.Valuation 97
Weaknesses
- Margin fallingOperating margin 20.5%, average of the prior years 32.6% (to 2024).Profitability 56
Its standout strengths are valuation and fundamentals, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $160.70 and expensive above $241.05 (uncertainty low, based on the price swings of the past year).
Calculated with a cost of equity of 7.8%. At 8.8% the fair value would be $159.60, at 6.8% it would be $242.80.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 21%, net not measured.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 30 Oct 2026EPS reported $2.80 (expected $2.00)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $9.54+0.5%
- Revenue
- $55.33B+1.7%
- Earnings per share
- $10.16+0.2%
- Revenue
- $58.79B+1.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sanofi
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Gilead SciencesGILD $210.52B58
- Novo NordiskNOVO-B.CO $178.97B79
- PfizerPFE $167.86B61
- Bristol-Myers SquibbBMY $128.59B71
- GSKGSK $101.43B70
- Chugai Pharmaceutical4519.T $73.85B78
- BayerBAYN.DE $62.05B53
- Otsuka Holdings4578.T $39.66B78
ETFs that hold Sanofi
Held by 171 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi CAC 40 ESG UCITS ETF AccGC40 | 6.47% | 0.25% | €717.1M |
| Amundi MSCI EMU High Dividend UCITS ETF Acc18M2 | 5.89% | 0.30% | €397.06M |
| Xtrackers CAC 40 UCITS ETF 1DDX2G | 5.32% | 0.20% | €128.63M |
Show 5 more
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 5.19% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 5.18% | 0.18% | €954.9M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 5.14% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 5.06% | 0.46% | €729.65M |
| iShares MSCI France UCITS ETFIS3U | 5.02% | 0.25% | €176.35M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Apr 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.